In Sickle cell disease OMIM 603903 (HBB, OMIM 603903), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4083, γ 1.2779, spinodal 0.5560). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Sickle cell disease OMIM 603903 is an R19 double-well emerged from the real proximal-promoter DNA of HBB. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.2779
barrier
0.4083
spinodal
0.5560
s_on / s_off
1.1304 / -1.1304
fragility
0.91
corrective polarity
clear
forced direction
raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4083 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating BCL11A does NOT relieve the disease branch in a HBB model, the h-restore(clear) lever is refuted for this axis.
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual HBB allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: BCL11A erythroid-enhancer disruption (exagamglogene autotemcel / exa-cel); HbF inducer (hydroxyurea). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. An autologous haematopoietic stem-cell therapy transduced ex vivo with a lentiviral vector encoding an anti-sickling adult beta-globin (HbA-T87Q); the T87Q residue sits at a deoxy-HbS contact and interferes with HbS polymerisation, so red cells carrying the engineered globin sickle far less. Direction on the disease axis: decrease / clear the HbS-polymerisation and sickling drive -- distinct from the fetal-haemoglobin-INDUCTION lever (hydroxyurea and the HbF-editing gene therapies) which is an increase action the corpus surfaces on the beta-thalassaemia node. Engaged node: HBB (the beta-globin locus). Allele scope: agnostic with respect to the sickle variant. Gene-specific to HBB; encoded as a decrease lever and approved for sickle cell disease only, so the join surfaces it on sickle_cell_disease and not on the increase/stabilise beta-thalassaemia node. Modality: a one-time approved ex-vivo gene therapy requiring conditioning, carrying a boxed haematologic-malignancy warning; the decrease direction recovers an approved indication.
✓ This is a rediscovery. Lovotibeglogene autotemcel (ex-vivo lentiviral anti-sickling HbA-T87Q beta-globin HSC gene therapy) is approved for sickle cell disease with vaso-occlusive events; the engineered anti-sickling globin disrupts HbS polymerisation, which is the disease-axis decrease direction, recovering an approved indication. Encoded as a decrease lever and approved for sickle cell disease only, so it is not surfaced on the beta-thalassaemia node (increase / stabilise). Note: the cornerstone agent hydroxyurea is encoded in the corpus as an HbF-INDUCTION (increase) lever and therefore surfaces on the thalassaemia node, not here -- an honest consequence of the sign convention. Boxed warning for haematologic malignancy; conditioning required; access/cost and current-availability caveats.
Safety (qualitative; no magnitude). boxed warning for haematologic malignancy; requires myeloablative conditioning; engraftment and conditioning-related signals (qualitative; no magnitude); specialised centre; one-time administration; access and cost barriers, and current commercial availability should be confirmed
Falsifier. If lovotibeglogene autotemcel (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a HBB model, the h-restore(clear) direction is refuted for lovotibeglogene autotemcel here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of HBB; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).